Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
2022年 12月 05日
Read MoreZai Lab to Present Interim Overall Survival Results for ZEJULA® (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary
2022年 12月 01日
Read MoreZai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
2022年 11月 09日
Read MoreZai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
2022年 11月 08日
Read MoreZai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
2022年 11月 08日
Read MoreZai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
2022年 10月 18日
Read More